Management and Prevention of Diabetic Complications

Chapter

Abstract

Type 2 diabetes is a chronic disease characterized by insulin resistance, impaired insulin secretion, and hyperglycemia. The long-term complications of diabetic retinopathy, nephropathy, neuropathy, and accelerated atherosclerosis lead to significant morbidity in the form of preventable blindness, end-stage renal disease (ESRD), limb amputations, and premature cardiovascular disease (CVD) [1]. Although patients with diabetes suffer from the morbidity of their microvascular complications, the majority of them ultimately die from the complications of macrovascular coronary artery disease (CAD).

Keywords

Placebo Cholesterol Albumin Creatinine Superoxide 

References

  1. 1.
    http://diabetes.niddk.nih.gov/DM/PUBS/statistics/ Accessed September 5, 2009.Google Scholar
  2. 2.
    De Fronzo RA: Lilly Lecture 1987: The triumvirate: β cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988, 37:667–687.Google Scholar
  3. 3.
    Pratley RE, Weyer C: The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001, 44:929–945.PubMedCrossRefGoogle Scholar
  4. 4.
    Reaven GM: Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005, 47:201–210.PubMedGoogle Scholar
  5. 5.
    Fagan TC, Deedwania PC: The cardiovascular dysmetabolic syndrome. Am J Med 1998, 105:77 S–82 S.PubMedCrossRefGoogle Scholar
  6. 6.
    Wilson PW, D’Agostino RB, Parise H, et al.: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066–3072.PubMedCrossRefGoogle Scholar
  7. 7.
    Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615–1625.PubMedCrossRefGoogle Scholar
  8. 8.
    Brownlee M: Biochemistry and molecular cell biology of ­diabetic complications. Nature 2001, 414:813–820.PubMedCrossRefGoogle Scholar
  9. 9.
    UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837–853.CrossRefGoogle Scholar
  10. 10.
    UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854–865.CrossRefGoogle Scholar
  11. 11.
    UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 7160:703–713.CrossRefGoogle Scholar
  12. 12.
    Buse JB, Ginsberg HN, Bakris GL, et al.: American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114–126.Google Scholar
  13. 13.
    Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.CrossRefGoogle Scholar
  14. 14.
    Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, et al.  : How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diabet Med 2008, 25:1433–1439.PubMedCrossRefGoogle Scholar
  15. 15.
    Fong DS, Aiello LP, Ferris FL 3 rd, et al.: Diabetic retinopathy. Diabetes Care 2004, 27:2540–2553..Google Scholar
  16. 16.
    American Diabetes Association: Position statement: diabetic retinopathy. Diabetes Care 2004, 27:S84–S87.CrossRefGoogle Scholar
  17. 17.
    Gordois A, Scuffham P, Shearer A, Oglesby A: The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complicat 2004, 18:18–26.PubMedCrossRefGoogle Scholar
  18. 18.
    American Diabetes Association: Position statement: diabetic nephropathy. Diabetes Care 2004, 27:S79–S83.CrossRefGoogle Scholar
  19. 19.
    American Diabetes Association: Clinical practice recommendations 2009. Diabetes Care 2011, 34:1–61.CrossRefGoogle Scholar
  20. 20.
    Friedman E: Renal syndromes in diabetes. Endocrinol Metab Clin North Am 1996, 25:293–324.PubMedCrossRefGoogle Scholar
  21. 21.
    Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.CrossRefGoogle Scholar
  22. 22.
    Harati Y: Diabetic neuropathies: unanswered questions. Neurol Clin 2007, 25:303–317.Google Scholar
  23. 23.
    Vinik A, Ullal J, Parson HK, et al.: Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab 2006, 2:269–281.PubMedCrossRefGoogle Scholar
  24. 24.
    Frykberg RG, Zgonis T, Armstrong DG, et al.: Diabetic foot ­disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2000, 39(Suppl 5):S1–S60.Google Scholar
  25. 25.
    American Diabetes Association: Position statement: preventive foot care in diabetes. Diabetes Care 2004, 27:S63–S64.CrossRefGoogle Scholar
  26. 26.
    Hidalgo-Tamola J, Chitaley K: Review type 2 diabetes mellitus and erectile dysfunction. J Sex Med 2009, 6:916–926.PubMedCrossRefGoogle Scholar
  27. 27.
    Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.Google Scholar
  28. 28.
    ADVANCE Collaborative Group, Patel A, MacMahon S, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.Google Scholar
  29. 29.
    Duckworth W, Abraira C, Moritz T, et al.: VADT investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139.Google Scholar
  30. 30.
    American Diabetes Association: Position statement: management of dyslipidemia in adults with diabetes mellitus. Diabetes Care 2004, 27:S68–S71.CrossRefGoogle Scholar
  31. 31.
    American Diabetes Association: Position statement: aspirin therapy in diabetes. Diabetes Care 2004, 27:S72–S73.CrossRefGoogle Scholar
  32. 32.
    Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.PubMedCrossRefGoogle Scholar
  33. 33.
    Eastman RC, Javitt JC, Herman WH, et al.: Model of complications in NIDDM: Analysis of the health benefits and cost-­effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997, 20:735–744.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Departments of Medicine, Endocrinology, and DiabetesVA San Diego Healthcare SystemSan DiegoUSA

Personalised recommendations